SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

News

Study from Scripps using SpyTag/SpyCatcher for display of SARS-CoV-2 RBD on ferritin nanoparticles for vaccine development

Published on 8 Oct 2020

Share

A study from Scripps using SpyTag/SpyCatcher technology shows that the receptor-binding domain and stabilized SARS-CoV-2 spike displayed on ferritin nanoparticles as vaccine antigens, elicited potent immune responses.

Click link here for the paper (14 Sept, 2020)

Read more about our pipeline and the diseases we are working to eradicate.

Our Pipeline